This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sugimura, K. Articles by Azuma, I. Search for Related Content PubMed PubMed Citation Articles by Sugimura, K. Articles by Azuma, I.

Tumor Growth Inhibitory Activity of a Lymphocyte Blastogenesis Inhibitory Factor¹

Institute of Immunological Science, Hokkaido University, Sapporo 060 [K. S., T. O., Y. W., T. K., I. A.], and Hayashibara Biochemical Laboratories, Inc., 675-1, Fujisaki, Okayama 702 [S. F.]

A lymphocyte blastogenesis inhibitory factor (LBIF) has been characterized as an immunoregulatory molecule, especially on the T-lymphocyte proliferation. Using fast protein liquid chromatography-purified LBIF, we examined the effect of LBIF on the proliferation of various 18 tumor cell lines in vitro in comparison with those of interferon-, interferon-, tumor necrosis factor-, transforming growth factor-ß1, or interleukin 1/ß. We showed here that LBIF strongly inhibited the proliferation of various tumor cell lines irrespective of cell lineage or species. LBIF was effective on a wider spectrum of tumor cell lines than other cytokines tested here. The inhibition resulted from cytotoxic or cytostatic effects, depending on individual characteristics of tumor cell lines. Five cell lines showed insensitivity against LBIF activity, suggesting a plausible involvement of LBIF receptor molecules to transduce LBIF signals. These results suggest that LBIF may play important roles in regulating cell growth.

¹ Supported by Grants-in-Aid for Cancer Research from the Japanese Ministry of Education, Science and Culture; from the Japanese Ministry of Health and Welfare for Comprehensive 10-Year Strategy for Cancer Control; from the Japanese Ministry of Education, Science and Culture for Scientific Research and for Developmental Scientific Research (No. 62870023); and from the Japanese Ministry of Education, Science and Culture for Scientific Research. It is also supported by the Osaka Foundation for Promotion of Clinical Immunology; by Yamanouchi Foundation for Research on Metabolic Disorders; by a Grant-in-Aid for Special Project Research from Hokkaido University; by Grants-in-aid from the Mochida Memorial Foundation for Medical and Pharmaceutical Research, and also by the Akiyama Foundation.

² To whom requests for reprints should be addressed, at Institute of Immunological Science, Hokkaido University, Sapporo 060, Japan.

Received 6/ 8/89. Revised 8/29/89. Accepted 10/10/89.

This article has been cited by other articles:

				F. Izzo, P. Marra, G. Beneduce, G. Castello, P. Vallone, V. De Rosa, F. Cremona, C. M. Ensor, F. W. Holtsberg, J. S. Bomalaski, et al. Pegylated Arginine Deiminase Treatment of Patients With Unresectable Hepatocellular Carcinoma: Results From Phase I/II Studies J. Clin. Oncol., May 15, 2004; 22(10): 1815 - 1822. [Abstract] [Full Text] [PDF]

				C. M. Ensor, F. W. Holtsberg, J. S. Bomalaski, and M. A. Clark Pegylated Arginine Deiminase (ADI-SS PEG20,000 mw) Inhibits Human Melanomas and Hepatocellular Carcinomas in Vitro and in Vivo Cancer Res., October 1, 2002; 62(19): 5443 - 5450. [Abstract] [Full Text] [PDF]